Skip to main content

Table 2 Changes in CXCL13 levels with different therapies in RA

From: A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

Study

Population

Study

Substrate

CXCL13 levels with treatment

Moura et al. (2017) [15]

N = 33. ERA, EstRA

Anti-TNF, anti-IL6R

Cohort

Serum by ELISA

No change with: ADA, GOL, ETN or TCZ

Rinaldi et al.* (2017) [33]

N = 34. EstRA Anti-IL6R

RCT

Serum, method not published

Reduction with anti-IL-6 (TCZ, vobarilizumab)

Han et al. (2016) [16]

N = 29. EstRA Anti-TNF

Cohort

Serum by ELISA

Reduction with TNF (ADA/ETN) in TNF responders

B/L high level associated greater response

Bugatti et al.* (2016) [34]

N = 205. ERA

csDMARD

Cohort

Serum, method not published

B/L high levels predict failure of remission

Kumagai et al.* (2016) [17]

N = 146. EstRA

Anti-TNF

Cohort

Serum by ELISA

Reduction with ADA in ADA responder.

Not seen with IFX

Loza et al.* (2016) [18]

N = 916. ERA

Anti-IL6

Cohort

Serum by ELISA, MSD, Luminex

No change with sirukumab

Bugatti et al.* (2016) [19]

N = 213. EstRA

csDMARD

Cohort

Both, method not published

B/L high levels predict failure of remission

Greisen et al. (2014) [23]

N = 114. ERA

csDMARD, Anti-TNF

Cohort

Serum by ELISA

Correlate with treatment response.

B/L high level predict ADA treatment remission

Bugatti et al.* (2014) [24]

N = 205

csDMARD

Cohort

Serum by ELISA

No change with treatment

de Jong et al. (2014) [35]

N = 18

Anti-CD20

Cohort

Serum by Luminex

Reduction with rituximab irrespective of responder status

El-Sherbiny et al.* (2013) [36]

N = 23

Anti-CD20

Cohort

Synovial by mRNA qPCR

Reduction with rituximab in rituximab responders

Taylor et al. (2017) * [37]

N = 65 EstRA

JAKi

RCT

Serum, method not published

Reduction with filgotinib. No change with placebo

Gabay et al. (2016) [38]

N = 356 EstRA

Anti-IL6R

RCT

Serum by ELISA

Reduction with sarilumab (p < 0.01) from 2 weeks

Boyle et al. (2015) [39]

N = 29 EstRA

JAKi

RCT

Serum by ELISA

Reduction with tofacitinib. No change with placebo

Dennis et al. (2014) [40]

N = 198. EstRA

Anti-TNF, anti-IL6R

RCT

Serum by ECLA

Low B/L levels associate greater response to ADA

High B/L levels associated greater response to TCZ

Kennedy et al. (2014) [41]

N = 214. EstRa

Anti-TNF, antiLTα

RCT

Serum by ELISA & MSD

Reduction with ADA and pateclizumab.

Herman et al. (2013) [42]

N = 325. EstRa

Anti-TNF, anti-IL6

RCT

Serum, method not published

Reduction with ADA, correlates with ADA response Reduction with TCZ, B/L high levels predict response

Emu et al. * (2012) [43]

N = 65

antiLTα

RCT

Serum by ELISA

Reduction with pateclizumab

Rosengren et al. (2011) [44]

N = 24, Anti-CD20

Cohort

Both by ELISA, mRNA qPCR

Reduction with rituximab at 2 months, which was maintained at 6 months

  1. * Abstract only. ERA Early RA, EstRA Established RA, HC Healthy control, csDMARDs Conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs Biologic disease-modifying anti-rheumatic drugs, TNFi Tumour Necrosis Factor inhibitor drug, ADA Adalimumab, ETN Etanercept, antiIL-6R Anti-interleukin 6 receptor. DAS28 Disease activity score for 28 joint count, SJC Swollen joint count, TJC Tender joint count, PGA Patient global assessment, RF Rheumatoid factor, ACPA Anti–citrullinated peptide antibodies